None listed
Conditions
Interventions
Intervention1: Red from paprika extract (solid and liquid form)
Yellow from turmeric extract
(solid and liquid form)
Green from Chlorophyll
(solid and liquid form)
Purple from Beet root
(only liquid f
Sponsors
Plant Lipids P Limited
Eligibility
Inclusion criteria
Inclusion criteria: • Males or females, age 21 to 65 years of age and in good general health • Individuals of any skin type or race provided their degree of skin pigmentation does not significantly interfere with evaluations • Individuals free of any systemic or dermatological disorder including known allergies to skin care products or topical drugs, or, other medical conditions which, in the opinion of the investigator, might interfere with the conduct of the study, interpretations of the results, or increase the risk of adverse reactions • Individuals able to understand, and provide written informed consent. • Individuals who are believed to be dependable, who agree to complete the course of the study, and comply with instructions.
Exclusion criteria
Exclusion criteria: • Women who are self-reported pregnant, nursing or planning a pregnancy • Individuals with a history of any dermatological disease or condition, including but not limited to active atopic dermatitis, psoriasis, eczema, active seasonal allergies or skin cancer within the past 6 months • Individuals with abnormal skin pigmentation at the test sites which might interfere with subsequent evaluations of dermal responsiveness • Individuals taking medications which might interfere with the test results, including any regimen of corticosteroids (equivalent to > 10 mg prednisone), steroidal/non-steroidal anti-inflammatory drugs, antihistamines or immunosuppressive drugs • Individuals who have applied any type of topical anti-inflammatory medication to the test sites within two weeks prior to enrollment • Individuals with any other skin condition that would interfere with the conduct of the study • Individuals who have undergone a bilateral mastectomy with lymph node removal, a unilateral mastectomy with lymph node removal within the last year, or a bilateral axillary lymph node removal • Individuals with a history of immune deficiency or auto-immune disease • Individuals who are currently receiving allergy injections, have received allergy injections within one week prior to enrollment, or expect to begin receiving allergy injections during the study • Individuals treated for malignancy within 6 months prior to enrollment • Individuals who are currently under treatment for asthma or diabetes • Current enrollment in any other research study or participation in a patch test study within 30 days prior to the start of this study • Individuals who are known tape/adhesive reactors • Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks. • Any psychiatric illness that prevents the subject from completing the study or interfere with the interpretation of the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of subjects with dermal sensitivityTimepoint: Day 0, 2, 4 and 7 | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess the dermal sensitivity using HRIPT ScaleTimepoint: Day 0, 2, 4 and 7 | — |
Countries
India
Contacts
Public ContactDAhmed Meeran
Aurous HealthCare R&D India Pvt. Ltd
Outcome results
None listed